BioNTech's Potential Winners Beyond Its COVID Vaccine

Keith Speights, The Motley Fool
·3-min read

BioNTech (NASDAQ: BNTX) now has its first commercial success story. Its COVID-19 vaccine BNT162b2 (which is being marketed under the brand name Comirnaty) should rake in a lot of money for the German biotech this year.